NBIS, CSCO, SLS Stocks Hit 52-Week Highs Today: What's Behind The Surge?

• Nebius reported a 654% year-on-year jump in its Q1 revenue.
• Cisco stock rose after it raised its 2026 AI order forecast to about $9 billion from $5 billion.
• Sellas advanced its leukemia trials, with key Phase 3 results nearing. 

Nebius Group (NBIS), Cisco Systems (CSCO), and Sellas Life Sciences Group (SLS) each climbed to fresh 52-week highs on Wednesday as investors rewarded companies delivering tangible progress in artificial intelligence infrastructure and drug development. 

Nebius and Cisco pointed to high demand from hyperscale customers building AI capacity, while Sellas moved closer to a potentially transformative milestone in leukemia treatment.

NBIS Rides AI Infrastructure Momentum

Nebius delivered explosive quarterly growth, with its first-quarter (Q1) revenue surging to $399 million, a dramatic 684% year-over-year increase that exceeded the Wall Street estimate of $388 million. The company also sharply increased its 2026 annual recurring revenue (ARR) outlook, projecting $7 billion to $9 billion.

The company further strengthened its AI infrastructure ambitions by securing access to up to 1.2 gigawatts of power capacity for a planned Pennsylvania-based AI computing facility. Investors viewed the move as a sign that Nebius is becoming a major provider of large-scale computing resources.

Nebius stock finished Wednesday’s session over 15% higher. On Stocktwits, retail sentiment around the stock changed to ‘extremely bullish’ from ‘bullish’ territory the previous day. 

CSCO Expands AI Push

Cisco stock continued its rally overnight on  Wednesday after the networking giant substantially raised its forecast for AI-related infrastructure orders. The company now expects approximately $9 billion in AI orders this fiscal year, up from its earlier estimate of $5 billion.

The company also revealed restructuring plans that include roughly 4,000 job cuts as it reallocates resources toward AI-focused networking hardware and silicon development. Cisco reported a 12% increase in its Q3 revenue to $15.8 billion with earnings per share of of $1.06, both beating the analysts’ consensus estimates of $15.6 billion and $1.04, respectively, according to Fiscal AI data. 

Cisco stock ended the day at nearl;y 3% higher. Retail sentiment around the stock remained in ‘extremely bullish’ territory. 

SLS Advances Cancer Programs

Sellas Life Sciences attracted investor attention after updating on the progress of its Phase 3 REGAL study evaluating Galinpepimut-S for acute myeloid leukemia (AML). The New York-based biotech said the trial is nearing its final event threshold needed for a key data readout.

The company said it has begun treating patients in a Phase 2 trial of SLS009 for high-risk AML. It also reported higher cash reserves, with over $107 million to fund its studies. 

Sellas Life Sciences' stock finished Wednesday 25% higher, with retail sentiment around the stock turning to ‘extremely bullish’ territory. 

So far this year, NBIS stock has surged over 147%, while SLS and CSCO stocks have gained 73% and 32%, respectively. 

Also See: Wendy's Stock Eyes Best Month In 6 years: Analyst Sees 46% Upside Amid Buyout, Revival Buzz

For updates and corrections, email newsroom[at]stocktwits[dot]com.